Dr. Reddy- The DRDO further said that uncontrolled diabetes, severe cardiac problem, ARDS, severe hepatic and renal impairment patients have not been studied yet with 2DG, and hence caution should be exercised.
Dr Reddy laboratories announced on Monday the commercial launch of the anti-Covid drug 2DG, developed by the Defense Research and Development Organization (DRDO). It comes after the DRDO said earlier on June 1 that the anti-Covid drug is approved for emergency use as an adjunct to standard of care in treating coronavirus patients in hospitals. .
“Ideally, 2DG should be prescribed as soon as possible by doctors for moderate to severe Covid patients for a maximum duration of up to 10 days,” he said.
DRDO further stated that uncontrolled diabetes, severe heart problems, ARDS, patients with severe hepatic and renal impairment have not yet been studied with 2DG, and therefore caution should be exercised. .
“2DG should not be given to pregnant and breastfeeding women and patients under the age of 18,” Dr. Reddy.
DRDO’s first batch of the anti-Covid-19 drugs was released on May 17 by Union Defense Minister Rajnath Singh and Health Minister Dr. Harsh Vardhan after the Comptroller General of Drugs of India (DCGI) has authorized the authorization for the emergency use of 2-deoxy-D-glucose (2-DG), an antiviral drug as an adjunct for patients with moderate to severe coronavirus.
The 2DG medicine comes as a powder in the sachet, which is taken orally by dissolving it in water. It accumulates in cells infected with the virus and prevents the growth of the virus by stopping viral synthesis and energy production. Its selective accumulation in cells infected with a virus makes this drug unique. The drug is said to reduce a patient’s average recovery time by two and a half days and reduce oxygen demand by up to 40%, the Union Health Ministry said.